One of China's largest pharmaceutical distributors, delivering drugs and medical supplies from manufacturers to hospitals and pharmacies.
One of China's largest pharmaceutical distributors, delivering drugs and medical supplies from manufacturers to hospitals and pharmacies.
Buys drugs and supplies from manufacturers and resells them to hospitals, clinics and pharmacies, keeping a small spread on large volumes while extending credit to customers, so working capital and volume matter more than price. Hospital procurement rules and national bulk drug-purchase programs shape the flow of business.
In one line: A Chinese McKesson/Cardinal Health.
Moat: narrow (scale, distribution, regulatory licence). Nationwide licensed distribution network and hospital relationships are costly to replicate.
Headquarters: Wuhan, Hubei, China · Employees: 29,862
Size Jointown Pharmaceutical (600998.SS) is a China Health Care company (Medical Distributors) with a market value of $3.99B, the 604th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.32 on 18 Nov 2026.
Performance Over six months the shares gained 7.5%, against +8.0% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 8.8% over the last twelve months (peer median +6.2%); the operating margin is 2.1% (peer median 3.1%).
Valuation It trades at 11.8× forward earnings against a peer median of 16.5× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.8 points below its cost of capital (5.0% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥172B | CN¥161B | CN¥152B | CN¥150B | CN¥140B |
| Revenue growth | — | +6% | +1% | +7% | — |
| Gross profit | CN¥13.9B | CN¥11.7B | CN¥11.0B | CN¥11.3B | CN¥10.2B |
| EBITDA | n/a | CN¥4.21B | CN¥4.74B | CN¥4.78B | CN¥4.18B |
| Net income | CN¥1.96B | CN¥2.25B | CN¥2.51B | CN¥2.17B | CN¥2.08B |
| Free cash flow | CN¥2.60B | CN¥2.14B | CN¥2.17B | CN¥3.73B | CN¥2.79B |
| Capital expenditure | CN¥1.26B | CN¥1.40B | CN¥975M | CN¥1.05B | CN¥1.24B |
| Total debt | CN¥51.2B | CN¥49.2B | CN¥42.6B | CN¥38.8B | CN¥40.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jointown Pharmaceutical 600998.SS | $3.99B | +7% | +9% | 2% | 11.8× | 0.2% |
| Sinopharm 1099.HK | $6.74B | 0% | +3% | 3% | 6.2× | -7.3% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| McKesson MCK | $125B | +44% | +8% | 2% | 22.1× | -5.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600998.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.0% | +1.2% | 4th highest of 20 |
| 6-month return | +7.5% | +8.0% | 9th lowest of 20 |
| Distance from 52-week high | -8.9% | -16.8% | 5th highest of 20 |
| Revenue growth (TTM) | +8.8% | +6.2% | 6th highest of 20 |
| Operating margin | 2.1% | 3.1% | 7th lowest of 20 |
| Forward P/E | 11.8× | 16.5× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 0.2% | -2.7% | 6th most demanding of 16 |
| Growth delivered (Del g) | +7.8% | +5.1% | 5th highest of 16 |
| Hurdle (Req g minus delivered) | -7.6 pp | -8.1 pp | 7th most demanding of 16 |
| ROIC minus cost of capital | -0.8 pp | +1.6 pp | 5th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jointown Pharmaceutical 600998.SS | China | $3.99B | +7% | +9% | 2% | 11.8× | 0.2% | +7.8% |
| MEDIPAL 7459.T | Japan | $3.70B | +15% | +4% | 1% | 12.5× | -7.2% | +3.5% |
| Amplifon AMP.MI | Italy | $3.39B | +8% | 0% | 10% | 17.0× | 6.8% | +9.8% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 15.9× | n/a | n/a |
| Galenica GALE.SW | Switzerland | $5.31B | +8% | +6% | 5% | 23.9× | 7.0% | +3.5% |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 18.4× | -8.4% | +3.5% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% | +12.7% |
| DKSH DKSH.SW | Switzerland | $5.99B | +24% | -1% | 3% | 21.8× | -1.2% | +0.6% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | n/a | 26.0% | +9.6% |
| Sinopharm 1099.HK | Hong Kong | $6.74B | 0% | +3% | 3% | 6.2× | -7.3% | +4.0% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Henry Schein HSIC | United States | $9.47B | +17% | +6% | 6% | 14.7× | 10.2% | +5.4% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |